BetterLife Pharma (TSE:BETR) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BetterLife Pharma has announced promising cardiac safety data for its LSD derivative, BETR-001, which shows minimal impact on crucial cardiac ion channels. This positive outcome positions the company closer to initiating clinical trials, advancing its efforts in developing treatments for neuro-psychiatric and neurological disorders.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue